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Abstract We have previously shown that neopterin enhances hydrogen peroxide and chloramine T activity in a luminol-dependent chemilumines- 
cence assay and strengthens toxicity of these agents against bacteria at slightly alkaline pH @H 7.5), while 7,8-dihydroneopterin was shown to be 
a scavenger independent of the pH value. Besides various oxidants, phenolic antioxidants were shown to specifically induce expression of the c-fos 
and c-&n mRNAs. Using an inducible cfosCAT reporter transactivation system we studied the function of the pteridine derivatives on c-fos 
transactivation. For the first time, we demonstrate that neopterin and 7,8_dihydroneopterin, particularly together with cyclic guanosine mono- 
phosphate, induce c-fos gene expression. In humans, interferon-y induces the release of neopterin and 7,8-dihydroneopterin and also the synthesis 
of nitric oxide radical which in turn stimulate the formation of cGMP. Thus, in certain situations all three substances, namely neopterin, 
7,8-dihydroneopterin and cGMP, may be present locally and even in the circulation at the same time. Based on our findings this constellation would 
significantly enhance the risk of c-fos gene expression and therefore promote tumour growth and development. 
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1. Introduction 
In humans, activation of the cellular immune system is asso- 
ciated with increased neopterin concentrations [l] because large 
amounts of neopterin are released from human monocytes/ 
macrophages upon stimulation with interferon-y. A concomi- 
tant production of 7,8_dihydroneopterin occurs in parallel. 
Recent data suggest that the formation of neopterin and 
7,8_dihydroneopterin is linked with the cytotoxic repertoire of 
activated macrophages because neopterin was found to be an 
enhancer for mechanisms mediated by reactive oxygen and 
chloride species [2,3] whereas 7,8_dihydroneopterin is a scaven- 
ger [24]. Both substances together may contribute to an en- 
dogenous redox equilibrium [5], the direction of its biological 
effect strongly depending on the pH and the presence of 
chelated iron 131. In addition, neopterin and 7,8-dihydroneo- 
pterin and other pteridine derivatives were shown to increase 
intracellular calcium in monocytic cells [6]. 
Among its pleiotropic activities, interferon-y induces the for- 
mation of nitric oxide in a variety of mammalian cells [7]. The 
thereby enhanced 5,6,7,8_tetrahydrobiopterin up-regulates the 
activity of inducible nitric oxide synthase [8]. Nitric oxide is a 
free radical which mediates some of its effects via the formation 
of cyclic guanosine monophosphate (cGMP) because NO acti- 
vates soluble guanylyl cyclase, most probably by binding to its 
heme group [9]. In mammalian cardiac myocytes it was shown 
that a cGMP-dependent protein kinase regulates intracellular 
Ca”-levels [IO]. Reactive oxygen species have been frequently 
implicated in the initiation and promotion of carcinogenesis. 
Direct effects on growth factors and other signalling pathways 
of both antioxidants and oxidants have recently been shown 
[l 11. Besides various oxidants, phenolic antioxidants were 
shown to specifically induce expression of c-fos and c-jun 
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mRNAs [12]. In this study, we explored the potential of neo- 
pterin, 7,8_dihydroneopterin and cGMP on c-fos gene expres- 
sion. 
2. Materials and methods 
2.1. Reagents 
Dulbecco’s modified Eagle’s medium (DMEM), fetal calf serum 
(FCS), L-glutamine, geneticin (G418) and acetyl-coenzyme A were ob- 
tained from Boehringer-Mannheim, Mannheim, Germany; RPM1 1640 
medium and FCS were purchased from Schoeller Phanna, Vienna, 
Austria. Neopterin and 7,8-dihydroneopterin were obtained from Dr. 
Schircks Laboratories, Jona, Switzerland and dissolved in Dulbecco’s 
phosphate-buffered saline (PBS) in glassware. Lysine-rich histone Hl 
(calf thymus-type III), 1,2-dioctanoyl-rat-glycerol (DAG), L-CC- 
phosphatidyl-L-serine (PS), phorbol 12,13_dibutyrate (PDBu), phorbol 
12-my&ate 13-acetate (TPA), guanosine 3’,5’-cyclic monophosphate 
(cGMP), leupeptin, and aprotinin were purchased from Sigma Chemi- 
cals, Munich, Germany. Silica gel-coated high performance thin layer 
chromatography plates (20 x 20 cm, No. 13181) were from Eastman 
Kodak Co., Rochester, NY, USA. [y-“P]ATP (30 Ci/mmol) was ob- 
tained from New England Nuclear (NEN, Vienna, Austria), and D- 
threo [dichloroacetyl-l-‘4C]chloramphenicol (57mCi/mmol) was sup- 
plied by Amersham, Little Chalfort, UK. Ethylacetate was obtained 
from Fluka Chemicals, Buchs, Switzerland. Multi-screen-HA 96-well 
filtration plates were from Millipore, Vienna, Austria. DEAE-cellulose 
(DE-52) was obtained from Whatman, Clifton, NJ, USA. 
2.2. Cell culture 
NIH3T3 fibroblasts were maintained in Dulbecco’s modified Eagle’s 
medium suuolemented with 2 mM L-glutamine, 10% fetal calf serum 
(FCS), SO,&‘ml gentamycin and inc&ted in a humidified atmosphere 
of 95% air with 5% C02. When confluent, the cells were passaged with 
a 1: 3 dilution procedure. Before treatment with various compounds, 
cells were made quiescent by incubation in DMEM medium containing 
0.5% FCS for 48 h. 
2.3. Plasmid construct: c-fos CAT promoter construct 
The c-fos(-711)CAT construct was obtained from P. Herrlich, 
Karlsruhe, Germany [13]. In the plasmid pcfos(-711)CAT the human 
C-/OS sequences from position -711 (XhoI site) to position +45 (XbaI 
site) are derived from the plasmid p(-750)fos and inserted into the .Sa!l 
and XbaI sites of the plasmid pBLCAT3 [14] (Fig. 1). 
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2.4. Cell transfection procedure 
NIH3T3 fibroblasts were grown at +37”C and 5% CO, in DMEM 
supplemented with 10% FCS. Stabile transfections of plasmid DNA 
w&i performed using the calcium phosphate co-precipitation tech- 
niaue. To obtain stable transfectants. NIH3T3 fibroblasts were co- 
traisfected with the appropriate plasmid constructs pcfos(-71l)CAT 
(5 pg), and the pSV2 neo plasmid (1 pg) and selected for geneticin 
(G418) resistance in DMEM medium containing 10% FCS and 700 
&ml G418. G418-resistant single colonies were isolated with trypsin- 
soaked filter discs. Cells derived from TPA-responsive colonies were 
propagated in selection medium to l-10 x lo6 cells and then used for 
further experiments. 
2.5. CAT assay 
Cellular extracts for determination of CAT activity in single clone 
cultures were made by freeze-thawing of cells that had been harvested 
with a plastic rubber in a solution of 0.25 M Tris-HC1, pH 7.8. After 
the cell extracts had been centrifuged at 500 x g for 2 min (+4”C) in a 
microfuge (Sigma, 2K 15), the supematants were analyzed for CAT 
activity 1141. The extracted materials were analyzed on silica gel thin- 
layer chromatography plates (20 x 20 cm, No. 13181; Eastman Kodak 
Company, Rochester, NY, USA) as described [15]. The protein concen- 
tration of each supernatant was determined by the method of Bradford 
[16]. Quantitation of CAT assays was performed by scintillation count- 
ing. 
2.6. Preparation of protein kinase C 
PKC was partially purified from NIH3T3 cells as described [I 71 with 
minor modifications. Cell extracts were prepared from logarithmically 
growing NIH3T3 cells (10 cm cell culture dishes). The medium was 
discarded, and the cell monolayer was rapidly washed twice with ice- 
cold Dulbecco’s PBS. All subsequent steps were carried out +4”C. The 
PBS solution was removed and the cells were collected and resuspended 
in homogenization buffer (50 mM Tris-HCI. DH 7.5. 50 mM mercan- 
toethanol, 1 mM phenylm&hylsulfonyl f uoiihe, 2 AM EGTA, O.l!% 
Triton X-100 (w/v), 20 fig/ml leupeptin, and 2 ,@ml aprotinin). The 
cells were disrupted by sonication (MSE sonifier at 60 W) and centri- 
fuged at 15,000 x g for 15 min, yielding crude nuclear pellets and post- 
nuclear supematants. The supematants were pooled and centrifuged at 
110,000 x g for 1 h and the resulting soluble membrane xtracts were 
applied onto DEAE-52 columns (2.5 x 8 cm; Whatman). Protein was 
eluted with a gradient from 0.0 to 0.17 M NaCl in elution buffer A 
(20 mM Tris-HCI, pH 7.5, 20 mM mercaptoethanol, 0.1 mM EGTA, 
0.1 mM EDTA, 2% glycerol). 
2.7. Determination of protein kinase C activity 
PKC (4.25 pg protein/25 ~1) was assayed by detecting the incorpora- 
tion of “P from [y-“P]ATP into histone Hl according to Aftab et al. 
[18]. Reactions (total volume of 125 ~1, containing 0.132 PM 
[r-‘*P]ATP, (30 Ci/mmol), 50 PM Na,ATP, 20 mM Tris-HCI, pH 7.4, 
1 mM CaCI,, 700 PM EGTA, 50 pg histone Hl type III, 1 PM PS and 
1.8pM DAG were set up in a 96-well plate. Non-specific phosphotrans- 
ferase activity was determined by using a lipid-free reaction mixture in 
the presence of EGTA. The assays were started by the addition of 
[y-‘*P]ATP with an eight-channel pipettor. After incubation for 15 min 
at +32”C the reactions were terminated by the addition of 50 ~1 20% 
trichloroacetic acid. The reaction mixtures were transferred to 96-well 
filter plates and filtered using a semiautomatic 96-well assay system. 
The filter disks (type HA, Millipore) were collected by using a filter 
punch apparatus (Millipore) and counted in a liquid scintillation 
counter. PKC activity was calculated as the difference of specific Ca”- 
and phospholipid-dependent PKC activity and non-specific 
phosphotransferase activity. 
3. Results 
NIH3T3 mouse fibroblasts were stably transfected with a 
cfosCAT construct containing the 5’-flanking sequence of the 
c-fis gene up to position -711 (Fig. 1). Expression of the cfos- 
CAT construct was stimulated by the known inducer of c-&s 
transcription phorbol 12,13-dibutyrate (PDBu) (Fig. 2). As 
shown in Fig. 2, the simultanious application of 7,%dihydro- 
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Fig. 1. Diagram of the plasmid vector used. The SRE contains a palin- 
dromic sequence known as the dyad symmetry element (DSE) and is 
located between position -321 to -299 (composed of the outer arm and 
the CArG box of the c-fos promoter [31]. In many systems activation 
through the SRE is mediated by a ternary complex assembled on the 
SRE consisting of the serum response factor (SRF) and a ternary 
complex factor (TCF/elk-I) [32]. Another sequence, the c-fos AP-I site 
(FAP), is localized immediately adjacent to the SRE (from -299 to 
-292). The FAP site (S-TGCGTCA-3’) is closely related to the AP-I 
consensus binding site (S-TGAGICTCA-3’). The FAP site is also impli- 
cated in the c-fos induction by CAMP via protein kinase A. Another 
element which confers a strong CAMP response, is the CAMP respon- 
sive element (CRE) located between positions -71 to -59 of the c-fos 
promoter [I 31. 
neopterin (400 nM) and cGMP (20 PM) led to a significant 
transcriptional activation of the cfosCAT reporter construct. 
A similar but less pronounced effect could be achieved by using 
neopterin and 7,8-dihydroneopterin. The direct effect of neo- 
pterin and 7,8_dihydroneopterin on c-fos transactivation was 
tested in the same experiment. As pointed out in Fig. 2, the 
direct transactivation of the cfosCAT reporter construct was 
marginal in comparison to the influence of the combination of 
neopterin derivatives with cGMP 
In order to investigate whether the induction of c-fos by 
neopterin or 7,8_dihydroneopterin alone or in combination 
with cGMP was mediated by PKC, the effects of the pterin 
derivatives were studied in cell-free extracts. As shown in Fig. 
3 neither 7,8_dihydroneopterin and neopterin nor cGMP alone 
or in combination with the pterines modulate PKC activity in 
vitro. 
4. Discussion 
In our study we show that 7,8_dihydroneopterin the pres- 
ence of cGMP strongly induces c-fos gene expression in 
NIH3T3 fibroblasts. A similar but less pronounced effect was 
achieved by using neopterin instead of 7,8_dihydroneopterin. 
There was also a direct effect of neopterin and 7,8-dihydro- 
neopterin on c-fos transactivation, however, it was diminished 
compared to the influence of the combinations of neopterin 
derivatives with cGMP. The effect induced by the combination 
of 7,8-dihydroneopterin and cGMP was similar to that which 
was observed when phorbol-esters like PDBu or a selected 
growth factor such as PDGF (data not shown), which are 
classical inducers of c-fos via activation of protein kinase C, 
were used. 
We have found that neither 7,8_dihydroneopterin and neo- 
pterin nor cGMP modulate activity of protein kinase C in cell- 
free extracts from NIH3T3 fibroblasts. Thus from this in vitro 
data, we conclude that these substances affect c-fos gene induc- 
tion downstream of the protein kinase C activation pathway, 
and have no direct effect on protein kinase C. 
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Fig. 2. Activation of cfosCAT expression by neopterin and 7,8-dihy- 
droneopterin together with cGMP. Stably cfosCAT-transfected 
NIH3T3 fibroblasts were growth arrested by incubation in 0.5% FCS 
for 48 h and CAT activity was induced by the addition of either 500 
nM PDBu or 20 PM cGMP, respectively. Where indicated, 400 nM 
neopterin and 7,8_dihydroneopterin alone or together with cGMP were 
added 18 h prior to cell harvesting. CAT activity was determined after 
administration of the agonists. (A) An autoradiograph of a representa- 
tive CAT assay (N represents neopterin and NH2 7,8dihydroneo- 
pterin, respectively. (B) Mean CAT activities were calculated from two 
independent experiments performed in duplicate and expressed asfold 
induction of uninduced controls (328 + 68 pmol/min/mg protein). 
It is not clear at present what the biochemical background 
of our observations is. It is possible that the effects are mediated 
via modulation of the Ca” current, which is known to strongly 
influence pathways of protein kinases [lo], but the antioxidant 
activity of 7,8_dihydroneopterin and other pterin derivatives 
[3-51 could also be important. Recently, induction of c-fos gene 
expression mediated by the serum responsive element (SRE) 
was demonstrated by various phenolic antioxidants such as 
butylated hydroxyanisole (BHA) or butylated hydroxytoluene 
(BHT) [12]. Promoter mapping results demonstrated that the 
c-fos promoter requires the SRE but not the adjacent AP-1 site 
for antioxidant-specific transactivation [12]. In contrast, a 
13 
recent report demonstrated that, under certain circumstances, 
AP-1 sites can be involved in the response to phenolic antioxi- 
dants [19]. The consensus equence of the antioxidant response 
element (ARE), S-ggTGACaaaGC-3’, of genes which are con- 
trolled by phenolic antioxidants, such as the NADP(H)-qui- 
none reductase [19] and the Ya-subunit of glutathione S-trans- 
ferase [20], is similar to the AP-1 consensus ite, S’-TGACTCA- 
3’. Although the biochemical basis for the activation of c-fos 
by antioxidants is still obscure, variations in redox parameters 
have been directly implicated in controlling the activation of 
several transcription factors, including c-Jun and c-Fos as well 
as NFKB and the glucocorticoid receptor [21]. If the antioxi- 
dant activity of 7,8-dihydroneopterin is important for the 
induction of c-fos gene expression, this could explain why neo- 
pterin is less active, because neopterin is much less an antioxi- 
dant than 7,8_dihydroneopterin; eopterin may even act as a 
prooxidant depending on the pH value [2,3]. 
The finding that neopterin derivatives directly support onco- 
gene expression may have some pathogenetic relevance with 
regard to human malignant diseases. Increased neopterin con- 
centrations correlate to the extent and activity of the disease in 
infections with viruses and intracellular bacteria, in autoim- 
mune disorders and in malignancies [l]. Moreover, neopterin 
concentrations were shown to bear predictive information, 
higher concentrations being associated with more rapid disease 
progression in patients with human immunodeficiency virus 
(HIV) infection [22,23] and in certain types of malignancies 
[24-261. This increase in neopterin concentrations appears to 
be invariably associated with a parallel rise in concentrations 
of a reduced derivative of neopterin, namely 7,8-dihydroneo- 
pterin, and concentrations of neopterin and 7,8-dihydroneo- 
pterin are closely related in humans. An approximate 2-fold 
excess of 7,8_dihydroneopterin was found when compared to 
neopterin in healthy individuals [27,28]. A similar relationship 
seems to exist during the status of immune activation, e.g. in 
homosexual men with HIV infection, concentrations of neo- 
pterin and of total neopterins (the sum of neopterin and its 
7,8-dihydro form) were of equal value in predicting the onset 
of AIDS [29]. 
Increased concentrations of cGMP are found in patients with 
cardiac disorders but also in malignant diseases [30]. However, 
in cancer patients the frequency of elevated concentrations of 
cGMP appears to be higher in urine than in plasma. In humans, 
interferon-y induces the release of neopterin and 7,8-dihy- 
droneopterin [I,291 and also the synthesis of the nitric oxide 
radical which in turn stimulates formation of cGMP [9]. Thus, 
in certain situations all three substances, namely neopterin, 
7,8-dihydroneopterin and cGMP, may be present locally and 
even in the circulation at the same time. This constellation 
would significantly enhance the risk of c-fos gene expression 
and therefore promote tumour growth and development. The 
prognostic value of higher neopterin concentrations to predict 
disease progression and death in malignant diseases could be 
related to the capacity of neopterin derivatives to induce onco- 
gene expression. The endogenous formation of cytokines at 
local sites of inflammation could be of importance within this 
context. 
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Fig. 3. Effect of 7&dihydroneopterin and cGMP alone, or in combination, on PKC activity. PKC partially purified from NIH3T3 fibroblasts was 
measured under standard conditions described in section 2. The enzyme (4.25 pg protein/25 ~1) was incubated for 15 min in the presence of 1 PM 
phosphatidylserine (PS) and 1 mM CaCl, (control, bar I) or fully activated by the addition of 1,2-dioctanoyl-rat-glycerol(l.8 PM DAG, bar 2). In 
bars 5-9, 1 l-15, as well as 17-21, increasing concentrations (0.1,0.2, 0.4,0.8, 1.6pM) of 7,8-dihydroneopterin, cGMP (5, lO,20, 50, 1OOpM) alone 
or in combination with cGMP (20 PM) were added in the absence of DAG. As a positive control the tumour promoter PDBu (1.8pM), which can 
fully activate nPKC isoforms by competing with the endogenous PKC activator DAG, was added to the assay (bar 3). Each bar represents mean 
values from two independent experiments, in which triplicate determinations were taken. 
References 
[l] Fuchs, D., Hausen, A., Reibnegger, G., Dierich, M.P., Werner, 
E.R. and Wachter, H. (1988) Immunol. Today 9, 15&155. 
[2] Weiss, G., Fuchs, D., Hausen, A., Reibnegger, G., Werner, E.R., 
Werner-Felmayer, G., Semenitz, E., Dierich, M.P. and Wachter, 
H. (1993) FEBS Lett. 329, 125-128. 
[3] Murr, C., Fuchs, D., Giissler, W., Hausen, A., Reibnegger, G., 
Werner, E.R., Werner-Felmayer, G., Esterbauer, H. and Wachter, 
H. (1994) FEBS Lett. 338, 223-226. 
[4] Kojima, S., Icho, T., Kajiwara, Y. and Kubota, K. (1992) FEBS 
Lett. 304, 193. 
[5] Uberall, F., Gruber, A., Wachter, H. and Fuchs, D. (1994) Immu- 
no]. Today (in press). 
[6] Wall, E., Weiss, G., Fuchs, D., Lang, F. and Wachter, H. (1993) 
FEBS Lett. 318, 249-252. 
[7] Nathan, C.F. (1992) FASEB J. 6, 3051-3064. 
181 Werner-Felmayer, G., Werner, E., Fuchs, D., Hausen, A., Reibe- 
negger, G. and Wachter, H. (1990) J. Exp. Med. 172, 1599-1607. 
[9] Ignarro, L.J. (1990) Pharmacol. Toxicol. 67, l-7. 
[IO] Mery, P.F., Lohmann, S.M., Walter, U. and Fischmeister, R. 
(1991) Proc. Nat]. Acad. Sci. USA 88, 1197-1201. 
[I l] Schreck, R., Abermann, K. and Baeuerle, P.A. (1994) Free Radic. 
Res. Commun. 17, 221-237. 
[12] Choi, H.S. and Moore, D.D. (1993) Mol. Endocrinol. 7, 1596 
1602. 
[13] Konig, H., Ponta, H., Rahmsdorf, U., Biischer, M., Schonthal, A., 
Rahmsdorf, J. and Herrlich, P. (1989) EMBO J. 8, 2559-2566. 
[14] Luckow, B. and Schiitz, G. (1987) Nucleic Acids Res. 15, 5490. 
[15] Doppler, W., Groner, B. and Ball, R.K. (1989) Proc. Natl. Acad. 
Sci. USA 86, 104-108. 
[16] Bradford, M.M. (1976) Analyt. Biochem. 72, 248-254. 
[l7] Uberall, F., Maly, K., Egle, A., Doppler, W., Hofmann, J. and 
Hans, H. Grunicke (1991) Cancer Res. 51, 5821-5825. 
[18] Aftab, D.T. and Hait, W.N. (1990) Anal. Biochem. 187, 8488. 
[19] Li, Y. and Jaiswal, A.K. (1992) J. Biol. Chem. 267, 15097-15104. 
[20] Favreau, L.V. and Pickett, C.B. (1991) J. Biol. Chem. 266,4556 
4561. 
[2l] Friling, ES., Bensimon, A., Tichauer, Y. and Daniel, V. (1990) 
Proc. Nat]. Acad. Sci. USA 87, 6258-6262. 
[22] Fuchs, D., Spira, T.J., Hausen, A., Reibnegger, G., Werner, E.R., 
Werner-Felmaver, G. and Wachter. H. (1989) Clin. Chem. 35, 
17461749. _ 
, 
[23] Fahey, J.L., Taylor, J.M.G., Detels, R., Hofmann, B., Melmed, 
R., Nishanian, P. and Giorgi, J.V. (1990) N. Engl. J. Med. 322, 
166172. 
[24] Reibnegger, G., Hetzel, H., Fuchs, D., Fuith, L.C., Hausen, A., 
Werner, E.R. and Wachter, H. (1987) Cancer Res. 47. 4977- 
4981. 
[25] Weiss, G., Kronberger, P., Conrad, F., Bodner, E., Wachter, H. 
and Reibneaaer, G. (1993) Cancer Res. 53, 260-265. 
[26] ReibneggeryG., Kramer, ‘M., Herold, M., Ludwig, H., Wachter, 
H. and Huber, H. (1991) Cancer Res. 51, 6250-6253. 
[27] Weiss, G., Glaser, K., Kronberger, P., Ambach, E., Fuchs, F., 
Bodner, E. and Wachter, H. (1992) Biol. Chem. Hoppe Seyler 373, 
3899394. 
[28] Kramer, A., Wiktor, S.Z., Fuchs, D., Milstien, S., Gail, M.H., 
Yellin, F.J., Biggar, R.R., Wachter, H., Kaufman, S., Blattner, 
W.A. and Goedert, J.J. (1987) J. Acq. Immun. Def. Synd. 2, 291- 
296. 
[29] Fuchs, D., Milstien, S., Kramer, A., Reibnegger, G., Werner, E.R., 
Goedert, J.J., Kaufman, S. and Wachter, H. (1989) Clin. Chem. 
35, 2305-2307. 
[30] Jakob, G., Mair, J., Vorderwinkler, K.P., Judmaier, G., Konig, P., 
Zwierzina. H.. Pichler. M. and Puschendorf, B. (1994) Clin. Chem. 
40,96-100. 
[31] Gutman, Wasylyk, C. and Wasylyk, B. (1991) Mol. Cell. Biol. 11, 
5381-5387. 
[32] Hipskind, R.A., Rao, V.N., Mtiller, C.G.F., Reddy, E.S.P. and 
Nordheim, A. (1992) Nature 354, 531-534. 
